Treatment of multifocal motor neuropathy with interferon-beta1A.
Nine patients with multifocal motor neuropathy who had previously responded favorably to IV immunoglobulins (IVIg) were treated with interferon-beta1a. Muscle strength and disability were evaluated. In six patients there was no effect of treatment. Four patients deteriorated in such a way that IVIg had to be restarted during the study. Three patients showed an improvement that was more pronounced than on IVIg. These patients had a shorter disease duration and were less affected clinically and electrophysiologically than those who did not respond.
Van den Berg-Vos
R M
RM
Departments of Neurology, Rudolf Magnus Institute for Neurosciences, University Medical Center Utrecht, the Netherlands.
Van den Berg
L H
LH
Franssen
H
H
Van Doorn
P A
PA
Merkies
I S
IS
Wokke
J H
JH
D000200:Action Potentials / Q000187:drug effects; D000328:Adult; D017668:Age of Onset; D020278:Demyelinating Autoimmune Diseases, CNS / Q000188:drug therapy*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016472:Motor Neuron Disease / Q000188:drug therapy*; D009046:Motor Neurons / Q000187:drug effects / Q000502:physiology; D009119:Muscle Contraction / Q000187:drug effects; D009431:Neural Conduction / Q000187:drug effects; D009481:Neurophysins; D010525:Peripheral Nerves / Q000187:drug effects / Q000503:physiopathology; D011597:Psychomotor Performance / Q000187:drug effects; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous; D009481:Neurophysins; D016899:Interferon-beta; D000068556:Interferon beta-1a